KELI Therapeutics is a clinical-stage biotech university spin-out company specializing in cell-based therapeutics. 

💼 Seeking Visionary Investors: We are currently raising 5 Mio EUR (24 months of the runway) to accelerate our lead program, KELI-101, in a First-In-Human, multi-center, adaptive Ph1/2A-B clinical trial (24 months)
🌱 Pioneering Allogeneic GMP-grade Placental Stem Cells: Backed by non-dilutive funding, our proprietary platform has undergone rigorous validation in four non-clinical animal studies, setting new benchmarks for therapeutic potential.
🧪 Expert Team of Biotech Innovators: Our interdisciplinary team boasts top-tier drug developers, regulatory experts, biotechnologists, and physicians, united in delivering groundbreaking medical breakthroughs.
💡 Scalable Manufacturing Excellence: Our placental stromal cell-based 2D/3D manufacturing platform ensures streamlined production of an extensive pipeline of advanced therapeutic medicinal products.
⚙️ Quality Control at the Core: Focusing on rigorous quality control measures, we underscore the safety and efficacy of our innovative therapeutic solutions.
💼 Collaborate for Success: Seeking partnerships with like-minded investors and biotech pioneers to drive healthcare innovation forward.
💰 Investment Opportunities: Join our transformative journey and explore potential significant returns on investment in the rapidly evolving biotech landscape.
🌍 Global Impact, Local Focus: Embrace the future of medicine as we bridge the gap between scientific advancements and patient-centric solutions with a global reach.

KELI Therapeutics

Org chart

Teams

Offices